Same molecule (tirzepatide), two very different products. Zepbound is FDA-approved and brand-name; compounded tirzepatide is cash-pay and not FDA-approved. Here's how cost, regulation, and access compare.
| Compounded tirzepatide | Zepbound® | |
|---|---|---|
| Maker | 503A / 503B pharmacies | Eli Lilly |
| FDA status | Not FDA-approved | FDA-approved (chronic weight) |
| Active ingredient | Tirzepatide | Tirzepatide |
| Mechanism | Dual GLP-1 / GIP | Dual GLP-1 / GIP |
| From / month | $186 (NexLife)* | $349–$1,059 |
| Insurance | Cash-pay (HSA/FSA) | Possible with coverage |
| Pivotal trial | (same molecule) | SURMOUNT-1 — 22.5% at 72 wk |
Verified July 2026. Zepbound LillyDirect self-pay vials sit at the low end of the brand range; pharmacy retail list near the high end.
Choose brand-name Zepbound if you want an FDA-approved product and either have insurance coverage or can use Lilly's self-pay vials. Choose compounded tirzepatide if you're cash-pay and want a lower predictable monthly cost — accepting that compounded products are not FDA-approved and that quality depends on the pharmacy. Either way, a licensed clinician decides eligibility.
For the flat-rate compounded option we rank #1, see the NexLife review. For pharmacy mechanics, see 503A vs 503B.